Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

BACKGROUND: This study aimed to explore the molecular mechanism and clinical relevance of iguratimod in the regulation of human B cell terminal differentiation. METHODS: An in vitro human antibody-secreting cell (ASC) differentiation system was established to test the effect of iguratimod. B cell ph...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Res Ther
Auteurs principaux: Ye, Yan, Liu, Mei, Tang, Longhai, Du, Fang, Liu, Yuanhua, Hao, Pei, Fu, Qiong, Guo, Qiang, Yan, Qingran, Zhang, Xiaoming, Bao, Chunde
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458835/
https://ncbi.nlm.nih.gov/pubmed/30971291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1874-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires